CN101948453B - Novel NEO-clerodane typed diterpene compound and application thereof - Google Patents
Novel NEO-clerodane typed diterpene compound and application thereof Download PDFInfo
- Publication number
- CN101948453B CN101948453B CN201010295997XA CN201010295997A CN101948453B CN 101948453 B CN101948453 B CN 101948453B CN 201010295997X A CN201010295997X A CN 201010295997XA CN 201010295997 A CN201010295997 A CN 201010295997A CN 101948453 B CN101948453 B CN 101948453B
- Authority
- CN
- China
- Prior art keywords
- compound
- fabms
- chromatographic column
- silica gel
- max
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides a novel NEO-clerodane typed diterpene compound which is obtained from the extraction and separation of sculellaria barbata. The preparation method comprises the following steps: weighting the whole plant of the sculellaria barbata, extracting by the reflux of methanol or alcohol, combining the extracting solution and reducing the pressure to concentrate; extracting the concentrated extract by the petroleum ether, the chloroform, the ethyl acetate and the n-butyl alcohol repeatedly, putting the chloroform extract on the silica gel column to perform the gradient elution by the petroleum ether-acetone, and then performing the column chromatography repeatedly through the silica gel, the reversed C18 column, the Sephadex LH-20 chromatographic column to obtain the product. The invention further provides a medicinal composition with the compound as the active component, a cancer cell activity restraining effect of the compounds and an application in the preparation of the antineoplastic medicines.
Description
The present invention is that application number is 200710106626.0, and the applying date is on May 22nd, 2007, and denomination of invention is divided an application for " new NEO-Crow alkane type diterpenoid and application thereof " one Chinese patent application.
Technical field
The present invention relates to new NEO-Crow alkane type diterpenoid, relate to the new NEO-Crow alkane type diterpenoid that from Herba Scutellariae Barbatae, extracts specifically.The invention still further relates to the application of this compound in suppressing tumour cell.
Background technology
Herba Scutellariae Barbatae (Scutellaria barbata D.Don) is a Labiatae Scutellaria plant, calls narrow leaf Indian Skullcap Herb, and head grass, toothbrush grass etc., with dry all herbal medicine.Its name is shown in " surgery authentic " the earliest, and flavor is hot, bitter, cold in nature, returns lung, liver, kidney channel, has clearing heat and detoxicating, stagnation resolvation, diuretic effect, is used to treat diseases such as furuncle swelling toxin, swelling and pain in the throat, venom, tumbling and swelling and oedema, jaundice.Among the people in China, often compatible Herba Scutellariae Barbatae and other herbal medicine, with treatment hepatitis and various cancer, like ovarian tumor, secondary pleurisy tumour, nasopharyngeal carcinoma, liver cancer, cancer of the stomach etc.
Contain number of chemical compositions such as flavonoid, sterol, terpene, vegeto-alkali, polysaccharide and organic acid in the Herba Scutellariae Barbatae; Up to the present, found that from Herba Scutellariae Barbatae [Xiao Haitao, Lee mill 13 NEO-Crow alkane type diterpene, Herba Scutellariae Barbatae chemical ingredients and pharmacology activity research progress; Traditional Chinese medicine research and information; 2005.7 (4), 20-22,25].The C of Scutebarbatine A only wherein
7The position is a chiral carbon atom.Through to domestic and international patent and literature search, do not find that so far NEO-Crow alkane type diterpene in the Herba Scutellariae Barbatae has the report of pharmacologically active.
In view of above reason, the inventor is through further investigation, and extraction separation has obtained a kind of new NEO-Crow alkane type diterpene from Herba Scutellariae Barbatae, and proves that it has the effect that suppresses growth of tumour cell.
Summary of the invention
The invention provides a kind of new NEO-Crow alkane type diterpenoid or its salt, its structural formula is following:
Formula I
Wherein:
R
1And R
2Independently be selected from: OH-, AcO-,
R
3Be selected from: OH-,
X is selected from
Formula II
Wherein:
R
4Be selected from OH-,
R
5, R
6Independently be selected from OH-or
Y is selected from
The formula III
Wherein:
R7 is selected from-CH2OAc or CH
3-;
R8 is selected from H-, OH-or
R9 is selected from H-, OH-or CH
3-;
N is selected from
M is selected from
R wherein
10, R
11Be independently selected from-OEt or hydrogen;
AB is singly-bound or two key.
The said compound of the present invention, specifically can for:
Formula I
Compound 1 (barbatin A):
R
2=OH-,
Compound 2 (scutebarbatine F): R
1=AcO-, R
2=AcO-,
Compound 3 (scutebarbatine I):
Compound 4 (scutebarbatine J):
R
2=AcO-,
Compound 5 (scutebarbatine K):
R
2=OH-, R
3=OH-,
Compound 6 (barbatin B): R
1=OH-,
Formula II
Compound 7 (barbatin C): R
4=OH-, R
5=OH-, R
6=OH-,
Compound 8 (scutebarbatine B):
R
5=OH-,
Compound 9 (scutebarbatine N):
R
5=OH-,
Compound 10 (scutebarbatine O): R
4=OH-,
R
6=OH-,
Compound 11 (scutebarbatine C):
R
5=OH-,
Compound 12 (scutebarbatine D):
R
5=OH-,
Compound 13 (scutebarbatine E):
R
5=OH-,
Formula III
Compound 14 (scutebarb atine G): AB is a singly-bound, R
7=-CH2OAc, R
8=-H, R
9=OH-,
R
10=-OEt, R
11=H-,
Compound 15 (scutebarbatineH): AB is a singly-bound, R
7=-CH2OAc, R
8=-H, R
9=-CH
3,
R
10＝H-，R
11＝-OEt，?
Compound 16 (scutebarbatine L): AB is two keys, R
7=-CH
3,
R
9=-OH,
Compound 17 (scutebarbatine M): AB is two keys, R
7=-CH
3, R
8=-OH, R
9=-OH,
The said salt of the present invention is meant pharmacy acceptable salt, the salt that for example forms with mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid.
The preparation method of compound provided by the present invention is: take by weighing a certain amount of Herba Scutellariae Barbatae herb, and with methyl alcohol or alcohol reflux 3-4 time, each 1-2 hour, united extraction liquid, concentrating under reduced pressure; Medicinal extract after concentrating extracts with sherwood oil, chloroform, ETHYLE ACETATE, propyl carbinol repeatedly; Get silicagel column on the chloroform extract; Carry out gradient elution with sherwood oil-acetone, use silica gel, anti-phase C18 post, Sephadex LH-20 chromatographic column column chromatography repeatedly then, promptly get.
Its concrete preparation method is: take by weighing a certain amount of Herba Scutellariae Barbatae herb, and with the methyl alcohol of 60-95% or alcohol reflux 3-4 time, each 1-2 hour, united extraction liquid, concentrating under reduced pressure; Medicinal extract after concentrating extracts with sherwood oil, chloroform, ETHYLE ACETATE, propyl carbinol repeatedly, gets silicagel column on the chloroform extract, with sherwood oil-acetone (97: 3-50: 50) carry out gradient elution, be divided into 7 parts (Fraction1-7).
Get wherein that Fraction2 crosses Rp C-18 chromatographic column, the methanol-water wash-out, then through Sephadex LH-20 chromatographic column purifying, compound 3 and compound 4;
Fraction3 crosses silica gel chromatographic column, and hexanaphthene-acetone gradient elution gets compound 9 and compound 16;
The last silica gel chromatographic column of Fraction4, hexanaphthene-acetone gradient elution gets a compound 2 and a mixture; Mixture through Rp C-18 chromatographic column, behind the methanol-water wash-out, through Sephadex LH-20 chromatographic column purifying, is got compound 14 and compound 15;
Fraction5 crosses silica gel chromatographic column, hexanaphthene-acetone gradient elution, compound 1, compound 6 and two mixture M 1, M2; Mixture M 1 is crossed Rp C-18 chromatographic column; The methanol-water wash-out then through Sephadex LH-20 chromatographic column purifying, gets compound 8 and compound 13; Mixture M 2 is crossed Rp C-18 chromatographic column, and the methanol-water wash-out then through Sephadex LH-20 chromatographic column purifying, gets compound 5,10 and 17;
Fraction6 crosses silica gel chromatographic column, and hexanaphthene-acetone gradient elution gets a compound 7 and a mixture; Mixture is crossed Rp C-18 chromatographic column, behind the methanol-water wash-out,, get compound 11 and compound 12 through Sephadex LH-20 chromatographic column purifying.
In order to increase the water-soluble of compound provided by the present invention, can form the sodium salt or the sylvite of Succinic anhydried, maleic anhydride, succinyl oxide etc., preferably its butanedioic acid derivative monopotassium salt.Said verivate can make according to ordinary method, also can obtain through following method:
Get compound and be dissolved in the anhydrous pyridine, add Succinic anhydried then, 80 ℃ were heated 50 minutes, added saleratus, stirred 30 minutes in the time of 50 ℃, promptly got the butanedioic acid derivative monopotassium salt.
The present invention also provides the Herba Scutellariae Barbatae extract that contains one or more NEO-Crow alkane type diterpenoids or its salt, and wherein NEO-Crow alkane type diterpenoid is medicinal significant quantity.
The present invention also provides compound and the Herba Scutellariae Barbatae extract restraining effect to tumour cell, and the application in preparation treatment antitumor drug.
Compound provided by the present invention or contain the Herba Scutellariae Barbatae extract of this compound can oral or non-oral forms administration, dosage is had nothing in common with each other because of compound is different, effective dose is 2mg/kg to 100mg/kg.
During the oral administration administration, can mix, be made into form administrations such as granule, capsule, soft capsule, tablet, dripping pill or oral liquid with the pharmaceutical excipient of routine such as weighting agent, disintegrating agent, tackiness agent, lubricant, seed dressing agent etc.During non-oral forms administration, can be prepared into injection liquid, lyophilized injectable powder, infusion solution etc.When preparing above-mentioned preparation, can use conventional preparation technique, but preferred method provided by the present invention.
Wherein said weighting agent can be selected from lactose, N.F,USP MANNITOL, starch, Microcrystalline Cellulose, the calcium sulfate etc. one or more; Wherein said disintegrating agent can be selected from low-substituted hydroxypropyl cellulose, the crosslinked sodium carboxymethylcellulose pyce that contracts, sodium starch glycolate, cross-linked polyvinylpyrrolidone, the Microcrystalline Cellulose etc. one or more; Wherein said tackiness agent is selected from one or more in hypromellose, Vinylpyrrolidone polymer, starch, methylcellulose gum, dextrin, the Icing Sugar etc.; Wherein said lubricant can be selected from one or more in Magnesium Stearate, calcium stearate, talcum powder, the micropowder silica gel etc.
Wherein said tablet can make according to following method: with compound provided by the invention or to contain Herba Scutellariae Barbatae extract and weighting agent, the disintegrating agent thorough mixing of this compound even; After sieving, add certain density binder solution and process softwood in right amount, scalping is granulated; Behind the dry whole grain; Add proper amount of lubricating agent, mixing, compressing tablet promptly gets.Also can select dressing behind the compressing tablet.
Wherein said injection liquid can make according to following method: with a certain amount of compound provided by the invention or contain the Herba Scutellariae Barbatae extract of this compound, add an amount of water for injection, stirring and dissolving; The pH value of regulator solution is used the activated carbon treatment after-filtration, measures midbody pH value and content; After qualified; Under aseptic condition with 0.22 μ m filtering with microporous membrane, embedding, sealing by fusing; 100 ℃ of flowing steam sterilizations promptly got in 30 minutes.
Wherein said lyophilized injectable powder can make according to following method: with compound provided by the invention or contain the Herba Scutellariae Barbatae extract of this compound, insert in the sterilized container, add an amount of water for injection; Stirring and dissolving adds certain density vehicle (be selected from lactose, sucrose, glucose, N.F,USP MANNITOL, gelatin hydrolysate, the DEXTRAN 500.000 etc. one or more) solution, the pH value of regulator solution behind the mixing again; Use the activated carbon treatment after-filtration, measure midbody pH value and content, qualified after; Under aseptic condition with 0.22 μ m filtering with microporous membrane; Packing filtrating, and add butyl rubber plug is put and is carried out lyophilize in the Freeze Drying Equipment and promptly get.
Embodiment
Following examples illustrate in greater detail the present invention, but do not limit the present invention in any form.
Embodiment one: the preparation of chloroform extract
Get 19.0 kilograms of Herba Scutellariae Barbatae herbs, 95% alcohol reflux 3 times, each 1 hour, united extraction liquid, concentrating under reduced pressure got about 1.0 kilograms of medicinal extract.Medicinal extract extracts with sherwood oil, chloroform, ETHYLE ACETATE, propyl carbinol repeatedly, and combined chloroform extraction liquid, concentrating under reduced pressure get chloroform extract 156.0 grams.
Embodiment two: the preparation of chloroform extract
Get 19.0 kilograms of Herba Scutellariae Barbatae herbs, 60% methanol eddy extracts 4 times, and each 1 hour, united extraction liquid, concentrating under reduced pressure got about 0.9 kilogram of medicinal extract.Medicinal extract extracts with sherwood oil, chloroform, ETHYLE ACETATE, propyl carbinol repeatedly, and combined chloroform extraction liquid, concentrating under reduced pressure get chloroform extract 148.0 grams.
Embodiment three: the preparation of compound
Get the last silicagel column of chloroform extract 147.8g among the embodiment one, be divided into 7 parts (Fraction 1-7) through sherwood oil-acetone [V/V, 97: 3-94: 6-90: 10-85: 15-80: 20-70: 30-50: 50] gradient elution.
Get 2.0 gram Fraction 2 and cross Rp C-18 chromatographic column, methanol-water (55: 45) wash-out then through Sephadex LH-20 chromatographic column purifying, gets compound 3 (15mg) and compound 4 (23mg).
Get 2.9 gram Fraction 3 and cross silica gel chromatographic column, hexanaphthene-acetone gradient elution gets compound 9 (18mg) and compound 16 (23mg).
Get 1.6 gram Fraction 4 and cross silica gel chromatographic column, hexanaphthene-acetone gradient elution gets compound 2 (8mg) and another mixture of 93mg; Through Rp C-18 chromatographic column, methanol-water (45: 55) wash-out at last through Sephadex LH-20 chromatographic column purifying, gets compound 14 (11mg) and compound 15 (27mg) with mixture.
Get 10.0 gram Fraction 5 and cross silica gel chromatographic column; Hexanaphthene-acetone gradient elution; Compound 1 (95mg), compound 6 (38mg) and two mixture M 1, M2, mixture M 1 is crossed Rp C-18 chromatographic column, methanol-water (55: 45) wash-out; Through Sephadex LH-20 chromatographic column purifying, get compound 8 (1.2g) and compound 13 (118mg) then; Mixture M 2 is crossed Rp C-18 chromatographic column, and methanol-water (50: 50) wash-out then through Sephadex LH-20 chromatographic column purifying, gets compound 5 (53mg), compound 10 (39mg) and compound 17 (40mg).
Get 2.1 gram Fraction 6 and cross silica gel chromatographic column, hexanaphthene-acetone gradient elution gets compound 7 (14mg) and another mixture of 81mg; Through Rp C-18 chromatographic column, methanol-water (45: 55) wash-out then through Sephadex LH-20 chromatographic column purifying, gets compound 11 (21mg) and compound 12 (13mg) with mixture.
Compound 1: white needle-like crystals; Mp150-151 ℃;
(c 0.12, MeOH).UV(CDCl
3)λ
max：219，255nm；IR(KBr)v
max：3430，1776，1668，1630，1600，1581，1460，1382，1021，760，720cm
-1；FABMS?m/z：575.2[M+H]
+，HR-FABMS?m/z：575.2649[M+H]
+(C
34H
39O
8，575.2645)。
Compound 2: white needle-like crystals; Mp 159-160 ℃;
(c 0.14, MeOH).UV(CDCl
3)λ
max：217，222，257；IR(KBr)v
max?cm
-1：1788，1731(br)，1642，1256，1229，1023，890，731；FABMS?m/z：556.2[M+H]
+；HR-FABMS?m/z：556.2506[M+H]
+(C
30H
38NO
9，556.2547)。
Compound 3: white needle-like crystals; Mp 150-152 ℃;
(c 0.13, MeOH).IR(KBr)v
max：1782，1731，1638，1589，1506，1474cm
-1；FABMS?m/z：682.2[M+H]+；HR-FABMS?m/z：682.2743[M+H]
+(C38H39N3O9，682.2765)。
Compound 4: white needle-like crystals; Mp 149-151 ℃;
(c 0.12, MeOH).IR(KBr)v
max：1781，1733，1642，1592，1500，1467cm
-1；FABMS?m/z：619.3[M+H]
+；HR-FABMS?m/z：619.2647[M+H]
+(C
34H
38N
2O
9，619.2656)。
Compound 5: white needle-like crystals; Mp 156-158 ℃;
(c 0.14, MeOH).IR(KBr)v
max：3450(br)，1771，1635，1609，1583，1467，1361cm
-1；FABMS?m/z：472.4[M+H]
+；HR-FABMSm/z：472.2331[M+H]
+(C26H33NO7，472.2335)。
Compound 6: white needle-like crystals; Mp148-150 ℃;
(c 0.13, MeOH).UV(CDCl
3)λ
max：220，256nm；IR(KBr)v
max：3455，1770，1661，1629，1608，1577，1458，1380，1013，770，721cm
-1，FABMS?m/z：575.3[M+H]
+，HR-FABMS?m/z：575.2653[M+H]
+(C
34H
39O
8，575.2645)。
Compound 7: white needle-like crystals; Mp 156-158 ℃;
(c 0.14, MeOH).UV(CDCl3)λ
max：220，257nm；IR(KBr)v
max：3438(br)，1713，1665，1638，1012cm
-1；FABMS?m/z：349.4[M+H]
+；HR-FABMS?m/z：349.2011[M+H]
+(C
20H
29O
5，349.2015)。
Compound 8: white needle-like crystals; Mp 151-153 ℃;
(c 0.13, MeOH).UV(CDCl
3)λ
max：17，222，257nm；IR(KBr)v
max：3342，1780，1743，1727，1643，1591，1501，1451，740，?712cm
-1；FABMS?m/z：558.3[M+H]
+；HR-FABMS?m/z：558.2487[M+H]
+(C
33H
36NO
7，558.2492)。
Compound 9: white needle-like crystals; Mp155-156 ℃;
(c 0.12, MeOH).IR(KBr)v
max：3442，1783，1731，1647，1593，1505，1450cm
-1；FABMS?m/z：573.4[M+H]
+；HR-FABMS?m/z：573.2241[M+H]
+(C32H32N2O8，573.2237)。
Compound 10: white needle-like crystals; Mp154-156 ℃;
(c 0.13, MeOH).IR(KBr)v
max：3449，1780，1729，1643，1590，1506，1460cm
-1；FABMS?m/z：454.3[M+H]
+；HR-FABMS?m/z：454.2227[M+H]
+(C33H34NO8，454.2230)。
Compound 11: white needle-like crystals; Mp 156-158 ℃;
(c 0.13, MeOH).UV(CDCl
3)λ
max：220，258；IR(KBr)v
max?cm
-1：3347，1781，1750，1643，1586，1485，1389，887，740，712；FABMS?m/z：574.3[M+H]
+；HR-FABMS?m/z：574.2396[M+H]
+(C
33H
36NO
8，574.2441)。
Compound 12: white needle-like crystals; Mp 151-153 ℃;
(c 0.12, MeOH).UV(CDCl
3)λ
max：221，260；IR(KBr)v
max?cm
-1：3340，1778，1739，1718，1635，1590，1475，390，883，747，719；FABMS?m/z：574.4[M+H]
+；HR-FABMS?m/z：574.2398[M+H]
+(C
33H
36NO
8：574.2441)。
Compound 13: white needle-like crystals; Mp 154-156 ℃;
(c 0.13, MeOH).UV(CDCl
3)λ
max：220，259；IR(KBr)v
max?cm
-1：3444，1780，1742，1705，1640，1586，1470，1400，888，733，710；FABMS?m/z：572.3[M+H]
+；HR-FABMS?m/z：572.2239[M+H]
+(C
33H
34NO
8，572.2284)。
Compound 14: white needle-like crystals; Mp 151-153 ℃;
(c 0.13, MeOH).IR(KBr)vmax：1725，1710，1591，1477，1439，1248，890，729cm
-1；FABMS?m/z：544.2[M+H]
+；HR-FABMSm/z：544.2923[M+H]
+(C
30H
41NO
8，554.2910)。
Compound 15: white needle-like crystals; Mp 151-153 ℃;
(c 0.12, MeOH).IR(KBr)v
max：1726，1710，1590，1478，1440，1251，888，730cm
-1；FABMS?m/z：544.3[M+H]
+；HR-FABMSm/z：544.2919[M+H]
+(C30H41NO8，554.2910)。
Compound 16: white needle-like crystals; Mp 153-154 ℃;
(c 0.13, MeOH).IR(KBr)v
max：3341，1770，1736，1639，1601，1513，1448cm
-1；FABMS?m/z：575.3[M+H]
+；HR-FABMS?m/z：575.2387[M+H]
+(C32H34N2O8，575.2392)。
Compound 17: white needle-like crystals; Mp 157-159 ℃;
(c 0.14, MeOH).IR(KBr)v
max：3450，1783，1740，1641，1588，1512，1459cm
-1；FABMS?m/z：470.4[M+H]
+；HR-FABMS?m/z：470.2173[M+H]
+(C26H31NO7，470.2179)。
Compound 1-17's
1H-NMR with
13C NMR data are seen table 1 to table 6.
Table 1: compound 1-10's
1H-NMR data (400MHz, in CDCl
3)
Ab
The a chemical shift representes that with ppm coupling constant J representes with Hz, and is placed in the bracket
The b chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Table 2: compound 6-10's
1H-NMR data (400MHz, in CDCl
3)
Ab
The a chemical shift representes that with ppm coupling constant J representes with Hz, and is placed in the bracket
The b chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Table 3: compound 11-14's
1H-NMR data (400MHz, in CDCl
3)
Ab
The a chemical shift representes that with ppm coupling constant J representes with Hz, and is placed in the bracket
The b chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Table 4: compound 15-17's
1H-NMR data (400MHz, in CDCl
3)
Ab
The a chemical shift representes that with ppm coupling constant J representes with Hz, and is placed in the bracket
The b chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Table 5: compound 1-10's
13C NMR data (100MHz, in CDCl
3)
a
The a chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Table 6 compound 11-17's
13C NMR data (100MHz, in CDCl
3)
a
The a chemical shift confirm to utilize HMQC, HMBC,
1H-
1H COSY technology
Test Example one: extracorporeal suppression tumor cell activity test
1, suppress the activity of tumor cells experimental technique:
With the RPMI-1640 culture medium culturing human nasopharyngeal carcinoma HONE-1 cell, oral epithelium cancer KB cell, the colorectal carcinoma HT29 cell that contain 5% foetal calf serum.Tumour cell is in the logarithmic growth after date and changes 24 well culture plates over to, and cell concn is 5000/ml/ hole.Add the soup to be measured of different concns in the culture hole, cultivated 72 hours.With the methylene blue assay method estimate medicine to press down oncocyte active.With the control group is reference, calculates IC with graphics
50Value.
Herba Scutellariae Barbatae ethanol extraction: make by [Wang Gang, Dong Mei etc., the research of Chinese medicine Herba Scutellariae Barbatae extract anti tumor activity in vitro, traditional Chinese medicine research and information, 2006.28 (9), 701-702] said method.
2, suppress the activity of tumor cells experimental result:
Use the methylene blue assay method, with Podophyllum emodi var chinense ethylidene and the positive contrast medicine of cis-platinum, having estimated Herba Scutellariae Barbatae ethanol extraction and 17 kinds of compounds, to press down oncocyte active.As shown in table 7, the result shows: 17 compounds all have the tumour cell effect (P＜0.01) that significantly presses down, and its anti-tumor activity obviously is better than Herba Scutellariae Barbatae extract.
Table 7 compound 1-17 presses down HONE-1, KB and HT
29The cancer cells experimental result
A, IC
50Representative makes tumor cell number reduce by 50% drug level.The result with 3 times independently the mean of revision test+-standard deviation representes.
B, positive control drug (Etoposide is the Podophyllum emodi var chinense ethylidene, and Cisplatin is a cis-platinum).
Test Example two: the medium lethal dose(LD&-{50}) (LD of intravenous administration
50) measure
1, test materials
Sample: the butanedioic acid derivative monopotassium salt of compound 3 (scutebarbatine I), compound 7 (barbatin C), compound 8 (scutebarbatine B), compound 16 (scutebarbatine L);
Animal: cleaning level Kunming kind small white mouse, body weight 18～22g is provided credit number by Shandong Luye Pharmaceutical Co., Ltd.'s animal center: SYXK (Shandong) 20030020.
Software: DAS medical statistics software
2, TP
Preliminary experiment is got 20 of mouse, carries out pilot study by sequential method, records mouse mainline 100% lethality rate and does not have administration maximal dose under the situation of causing death, and observes 7d continuously, result such as table 8.
Table 8 mouse mainline pilot study result
Formal experiment confirms that by the Bliss method high dosage to dosage ratio between the group of low dosage, is divided into 6 groups, 10 every group.Take by weighing the mouse body weight, press the administration of 0.2ml/10g tail vein injection, each is organized injection liquid concentration and calculates definitely according to mouse 20g mean body weight level, observes 7d continuously, result such as table 9.。
Table 9 mouse mainline LD
50Measure the result
3, test-results
Obtain the LD of compound 3 with DAS medical statistics computed in software
50Be 108.04mg/kg, the 95% credible 99.48mg/kg～117.34mg/kg that is limited to; The LD of compound 7
50Be 143.04mg/kg, the 95% credible 131.22mg/kg～155.92mg/kg that is limited to; The LD of compound 8
50Be 171.49mg/kg, the 95% credible 157.17mg/kg～187.12mg/kg that is limited to; The LD of compound 16
50Be 112.48mg/kg, the 95% credible 100.12mg/kg～126.37mg/kg that is limited to.
Test Example three: oral administration medium lethal dose(LD&-{50}) (LD
50) measure
1, test materials
Sample: the butanedioic acid derivative monopotassium salt of compound 3 (scutebarbatine I), compound 7 (barbatin C), compound 8 (scutebarbatine B), compound 16 (scutebarbatine L);
Animal: cleaning level Kunming kind small white mouse, body weight 18～22g is provided credit number by Shandong Luye Pharmaceutical Co., Ltd.'s animal center: SYXK (Shandong) 20030020.
Software: DAS medical statistics software
2, TP
Preliminary experiment is got 20 of mouse, carries out pilot study by sequential method, records mouse mainline 100% lethality rate and does not have administration maximal dose under the situation of causing death, and observes 7d continuously, result such as table 1.
Formal experiment confirms that by the Bliss method high dosage to dosage ratio between the group of low dosage, is divided into 6 groups, 10 every group.Take by weighing the mouse body weight, press the administration of 0.2ml/10g tail vein injection, each is organized injection liquid concentration and calculates definite according to mouse 20g mean body weight level.Observe 7d continuously.
3, test-results
Obtain the LD of compound 3 with DAS medical statistics computed in software
50Be 406.23mg/kg, the 95% credible 374.02mg/kg～438.44mg/kg that is limited to; The LD of compound 7
50Be 378.52mg/kg, the 95% credible 352.96mg/kg～404.08mg/kg that is limited to; The LD of compound 8
50Be 298.67mg/kg, the 95% credible 283.52mg/kg～313.82mg/kg that is limited to; The LD of compound 16
50Be 305.42mg/kg, the 95% credible 293.30mg/kg～317.54mg/kg that is limited to.
Test Example four: drug administration by injection is tested three kinds of mice transplanted tumor Growth Inhibition
1, test materials
Sample: the butanedioic acid derivative monopotassium salt of compound 3 (scutebarbatine I), compound 7 (barbatin C), compound 8 (scutebarbatine B), compound 16 (scutebarbatine L); With behind the injection physiological saline solution under aseptic condition with 0.22 μ m filtering with microporous membrane, obtain the injection soup of desired concn.
Endoxan: be Hualian Pharmaceutical Co., Ltd., Shanghai (lot number 040205), face with preceding with the injection physiological saline solution and be diluted to desired concn.
Animal and knurl strain: cleaning level Kunming kind small white mouse, body weight 18～22g is provided credit number by Shandong Luye Pharmaceutical Co., Ltd.'s animal center: SYXK (Shandong) 20030020.The male and female dual-purpose, same sex mouse is selected in each experiment for use.
Mouse H22 liver cancer, U14 cervical cancer and S180 sarcoma are all drawn from institute of materia medica, Chinese Academy of Medical Sciences Beijing.
2, TP
The preservation of going down to posterity of tumour: H22 liver cancer, U14 cervical cancer and S180 sarcoma are got the ascites preservation of going down to posterity after Kunming mouse abdominal cavity inoculation.
Tumor inoculation: get H22 liver cancer, U14 cervical cancer or S180 sarcoma tumor-bearing mice that ascites went down to posterity the 10th; Take off cervical vertebra and put to death mouse; The sterilization skin of abdomen is drawn oyster white ascites with asepsis injector, is 1 * 107 cell/ml with injection saline water adjustment tumour cell concentration.With cotton ball soaked in alcohol sterilization Kunming mouse right side armpit skin, in the above-mentioned tumor cell suspension 0.2ml of subcutaneous vaccination, the conventional raising.
Divide into groups and administration: 50 of tumor-bearing mices, be divided into 5 groups at random by body weight, 10 every group, be respectively model group, endoxan group, the high, medium and low dose groups of compound group.Each organize mouse press shown in dosed administration, model group tail every day vein waits volume injection to use saline water, endoxan is inoculation once abdominal cavity injection administration in second day, the compound group was from beginning tail vein injection administration every day 1 time on the secondth, continuous 10 days.After the last administration 24 hours, each treated animal is taken off cervical vertebra put to death, weigh, strip tumor tissue and weigh, calculate tumour inhibiting rate.
The result representes with
; Adopt the t check to carry out statistical comparisons between group, experimental result is seen table 10-13 respectively.
2, test-results
The result shows that the butanedioic acid derivative monopotassium salt tail vein injection administration of compound 3, compound 7, compound 8, compound 16 all has the obvious suppression effect to mice transplanted tumor H22 liver cancer, U14 cervical cancer and S180 sarcoma; Explain that these compounds have stronger antitumor activity in vivo; Can obviously suppress above-mentioned various growth of tumor (P＜0.01) during tail vein injection administration 10mg/kg dosage, during 50mg/kg dosage to the tumour inhibiting rate of above-mentioned tumour all greater than 60%.
The butanedioic acid derivative monopotassium salt of table 10 compound 3 suppresses the test-results of three kinds of knurl strain growths
The butanedioic acid derivative monopotassium salt of table 11 compound 7 suppresses the test-results of three kinds of knurl strain growths
The butanedioic acid derivative monopotassium salt of table 12 compound 8 suppresses the test-results of three kinds of knurl strain growths
The butanedioic acid derivative monopotassium salt of table 13 compound 16 suppresses the test-results of three kinds of knurl strain growths
Test Example five: oral administration is tested three kinds of mice transplanted tumor Growth Inhibition
1, test materials
With Test Example four.
2, TP
With Test Example four.
3, test-results
The result shows that the butanedioic acid derivative monopotassium salt oral administration of compound 3, compound 7, compound 8, compound 16 all has the obvious suppression effect to mice transplanted tumor H22 liver cancer, U14 cervical cancer and S180 sarcoma; Explain that these compounds have stronger antitumor activity in vivo; Can obviously suppress above-mentioned various growth of tumor (P＜0.01) during oral administration 50mg/kg dosage, during 100mg/kg dosage to the tumour inhibiting rate of above-mentioned tumour all greater than 60%.
Claims (2)
1. NEO-Crow alkane type diterpenoid, its structural formula is following:
Wherein:
R4 is selected from: OH-,
R5 and R6 independently are selected from: OH-or
Y is selected from:
Wherein, said compound is selected from:
Compound 7:R4=-OH; R5=-OH; R6=-OH,
Compound 8:
R5=-OH,
Compound 9:
R5=-OH,
Compound 10:R4=-OH;
R6=-OH,
Compound 11:
R5=-OH,
Compound 12:
R5=-OH,
Compound 13:
R5=-OH,
2. the application of the said compound of claim 1 in the preparation antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010295997XA CN101948453B (en) | 2006-05-23 | 2007-05-22 | Novel NEO-clerodane typed diterpene compound and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610081482.3 | 2006-05-23 | ||
| CN200610081482 | 2006-05-23 | ||
| CN201010295997XA CN101948453B (en) | 2006-05-23 | 2007-05-22 | Novel NEO-clerodane typed diterpene compound and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101066260A Division CN101077873B (en) | 2006-05-23 | 2007-05-22 | Novel NEO-clerodane type diterpene compound and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101948453A CN101948453A (en) | 2011-01-19 |
| CN101948453B true CN101948453B (en) | 2012-05-23 |
Family
ID=43452096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102960021A Expired - Fee Related CN101948473B (en) | 2006-05-23 | 2007-05-22 | New NEO-clerodane diterpenoid compound and application thereof |
| CN201010295997XA Expired - Fee Related CN101948453B (en) | 2006-05-23 | 2007-05-22 | Novel NEO-clerodane typed diterpene compound and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102960021A Expired - Fee Related CN101948473B (en) | 2006-05-23 | 2007-05-22 | New NEO-clerodane diterpenoid compound and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101948473B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104644743A (en) * | 2014-10-21 | 2015-05-27 | 中山大学 | Scutellaria barbata extract as well as preparation method and application thereof |
| CN105288603A (en) * | 2015-10-28 | 2016-02-03 | 杨廷稳 | Tumor vaccine for treating liver cancer and preparing method thereof |
| CN110687242B (en) * | 2019-07-03 | 2021-01-19 | 兰州大学 | Method for testing phytotoxicity activity of NEO-clerodane diterpenoid compounds on ryegrass |
| CN113499339A (en) * | 2021-07-06 | 2021-10-15 | 海南精准医疗科技有限公司 | Preparation method and application of traditional Chinese medicine clorine diterpenoid extracted from eleutherococcus senticosus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326343A (en) * | 1998-11-19 | 2001-12-12 | 白奥诺里卡股份公司 | Agent for lowering prolactin |
-
2007
- 2007-05-22 CN CN2010102960021A patent/CN101948473B/en not_active Expired - Fee Related
- 2007-05-22 CN CN201010295997XA patent/CN101948453B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326343A (en) * | 1998-11-19 | 2001-12-12 | 白奥诺里卡股份公司 | Agent for lowering prolactin |
Non-Patent Citations (2)
| Title |
|---|
| 张海方等.半枝莲化学成分及生物学活性的研究进展.《江苏大学学报(医学版)》.2006,第16卷(第1期),74-77. * |
| 肖海涛等.半枝莲化学成分和药理活性研究进展.《中药研究与信息》.2005,第7卷(第4期),20-22,25. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101948473A (en) | 2011-01-19 |
| CN101948453A (en) | 2011-01-19 |
| CN101948473B (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN101948453B (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
| TWI280881B (en) | Use of hederagenin 3-O-alpha-L-rhamnopyranosyl((1->2)-[beta-D-glucopyranosyl(1->4)]-alpha-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN105985358B (en) | Liu Yazi total alkaloid extract and its preparation method and application | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| KR20210047594A (en) | Compositions for reinforcing skin barrier and improving atopic dermatitis using hydrangenol or phyllodulcin as an active ingredient | |
| KR100740184B1 (en) | A composition contaning tectoridin or aglycone thereof for anti-cancer | |
| KR101491493B1 (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
| KR100733335B1 (en) | Fermentation Product of Puerariae Radix Extract and Composition for Prevention or Treatment of Osteoporosis Comprising the Same | |
| CN107629104A (en) | Triterpenoid saponin medical compounds and its preparation and application | |
| CN101591315B (en) | Novel homoisoflavone compound and application thereof | |
| CN102319379A (en) | Formula for treating and preventing cancerous tumors and preparation and production process of Chinese caterpillar fungus tumor rehabilitation oral liquid | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN101919903A (en) | Method for preparing rabdosia rubescens diterpene extract | |
| CN103735591B (en) | A kind of compositions of anti-peptic ulcer and application thereof | |
| CN103497871A (en) | Formulation method for blood-nourishing yin-nourishing health-care wine | |
| CN102188459A (en) | Brucea javanica total terpenoid extractive, and preparation method and application thereof | |
| CN102335180A (en) | Application of ursane compounds in preparing antitumor drugs | |
| CN101284860B (en) | Antineoplastic pharmaceutical compositions, preparation method and applications thereof | |
| KR20040036092A (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| CN101810624B (en) | Medicament for treating colon cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20210522 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |